Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.68
- Piotroski Score 5.00
- Grade Perform
- Symbol (MNK)
- Company Mallinckrodt plc
- Price $0.34
- Changes Percentage (-14.97%)
- Change -$0.06
- Day Low $0.30
- Day High $0.41
- Year High $16.00
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/09/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.78
- Trailing P/E Ratio -0.43615384615385
- Forward P/E Ratio -0.43615384615385
- P/E Growth -0.43615384615385
- Net Income $-717,400,000
Income Statement
Quarterly
Annual
Latest News of MNK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MannKind (MNKD) Q3 2024 Earnings Call Transcript
The Motley Fool Stock Advisor team identified the 10 best stocks for investors, excluding MannKind. MannKind is focusing on developing innovative treatments for diseases like NTM lung disease and IPF....
By Yahoo! Finance | 1 week ago -
HMS Networks AB (HMNKF) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...
The current market downturn is similar to past ones with weak demand in the embedded business. Cost reductions have been made, and further margin enhancements are challenging. Visibility on destocking...
By Yahoo! Finance | 1 month ago -
MannKind Corporation (MNKD): Short Seller Sentiment is Bearish
Insider Monkey analyzed the 14 worst 52-week high stocks to buy according to short sellers, focusing on MannKind Corporation (NASDAQ:MNKD). With the US Federal Reserve's rate cuts, the economy faces c...
By Yahoo! Finance | 2 months ago
